Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

CD4+CD25+Foxp3+T cell population is heterogenous and contains three major sub-groups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4+CD25+T cells gen...

Full description

Bibliographic Details
Main Authors: Bruce M. Hall, Rachael M. Hall, Giang T. Tran, Catherine M. Robinson, Paul L. Wilcox, Prateek K. Rakesh, Chuanmin Wang, Alexandra F. Sharland, Nirupama D. Verma, Suzanne J. Hodgkinson
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
interleukin-5
transplant tolerance
T regulatory cells
cytokines
allograft rejection
chronic rejection
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.714838/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.714838/full

Similar Items